Ceva expands through acquisitions
Oct. 6, 2011
by Bryan Salvage
GUELPH, Ontario – Ceva Santé Animale has acquired CentaurVA Animal Health, a division of Centaur Pharmaceuticals Inc., which manufactures and distributes products for small and large animal veterinary practitioners. Ceva has also acquired Vetech Laboratories Inc., a Canadian poultry vaccine manufacturer. Vetech produces live coccidiosis vaccines for poultry under the trade name Immucox.
The Centaur acquisition expands Ceva’s footprint in North America. Centaur’s broad range of products, including nutraceuticals, joint therapies and infection-control products, along with an experienced staff will provide Ceva with an excellent base for its expansion in the Canadian market, the company relayed.
“The move helps in marketing and distributing current Ceva products,” said Craig Wallace, North America Zone Director for Ceva, “and will serve as a strong foundation for future product launches.”
“Canada is an important world economy where we needed to have a direct presence,” said Marc Prikazsky, CEO of Ceva Sante Animale. “Integrating the two companies will lead to an expansion of networks for both teams, and continues Ceva’s growth into new markets.”
In North America, Ceva’s key companion animal products include the Vectra line of parasiticides, D.A.P. and Feliway pheromone behavior aids and Senilife neuroprotection for aging pets. Key poultry products include CEVAC Transmune IBD, Vectormune FP and Vectormune HVT. Ceva’s North America Zone headquarters are located in Lenexa, Kan.
Coccidiosis is a significant disease that can result in high morbidity and reduced feed efficiency in poultry. With the enforced global reduction of in-feed anti-coccidial products, it is likely that vaccines will become even more widespread.
“This [Vetech acquisition] allows Ceva to expand our poultry vaccine range from respiratory to also include intestinal health,” Prikazsky said. “We’re pleased to continue giving our business partners new options for keeping their operations healthy and productive.”
“Bringing the Immucox products into the Ceva portfolio demonstrates our continued commitment to the poultry industry,” said Craig Wallace, director of Ceva’s North American operations.
Immucox vaccines for breeders, layers, broilers, roasters and turkeys are now distributed in more than 40 countries worldwide. Production of Immucox will remain primarily in Canada. Ceva’s US operations can be scaled, and the company plans to deploy certain technologies in the US with this specific virus strain.